

CLAIMS

1. An antibody formulation suitable for subcutaneous administration to a patient, the formulation comprising:
 - a) about 100 to about 175 mg/mL of an antibody;
 - b) about 10 mM citrate buffer;
 - c) about 0.1% (w/v) surfactant, wherein the surfactant is a polysorbate;
 - d) about 200 mM arginine; and
 - e) about 4.5 to 9% sucrose,wherein the pH of the formulation is about pH 6, wherein the antibody is a fully human IgG4 anti-CXCR5 antibody, and wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 33 and a light chain comprising the amino acid sequence of SEQ ID NO: 32.
2. The antibody formulation of claim 1, wherein the antibody is an isolated that specifically binds to the extracellular domain of human CXCR5.
3. The antibody formulation of claim 2, wherein the isolated antibody comprises the amino acid sequences of RSSKSLLHSSGKTYLY (SEQ ID NO: 58), RLSSLA (SEQ ID NO: 68), MQHLEYPYT (SEQ ID NO: 60), GFSLIDYGVN (SEQ ID NO: 61), VIWGDGTTY (SEQ ID NO: 62), and IVY (SEQ ID NO: 63).
4. The antibody formulation of claim 1, wherein the polysorbate is polysorbate 20 or polysorbate 80.
5. An antibody formulation, comprising:
 - a) about 175 mg/mL of a humanized IgG4 anti-CXCR5 antibody;
 - b) about 10 mM citrate buffer;
 - c) about 1.0 mg/mL polysorbate 80;
 - d) about 200 mM arginine HCl; and
 - e) about 45 mg/mL sucrose, wherein the pH of the formulation is about pH 6, wherein the humanized IgG4 anti-CXCR5 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 33 and a light chain comprising the amino acid sequence of SEQ ID NO: 32.
6. A container comprising the antibody formulation of any one of claims 1-5.

7. The container of claim 6, wherein the container is a prefilled syringe, a vial, or an autoinjector.
8. A container comprising the antibody formulation of any one of claims 1-5 which has been lyophilized.
9. A kit, comprising the container of any one of claims 6, 7 or 8 and a label or instructions for the administration and use of the antibody formulation.
10. The kit of claim 9, wherein administration is by injection.
11. The antibody formulation according to any one of claims 1-5 for use in a method of diagnosis or treatment of the human or animal body.
12. An antibody formulation of any one of claims 1-5 for use in treating rheumatoid arthritis.
13. An antibody formulation of any one of claims 1-5 which has been lyophilized.